相关实验视频
Updated: May 7, 2025
04:52
A Modified Technique for Transverse Aortic Constriction in Mice
Published on: August 18, 2022
4.2K
在土耳其医疗和先进的心力衰竭疗法
Sanem Nalbantgil1, Emre Demir1, Ahmet Çelik2
1Department of Cardiology, Faculty of Medicine, Ege University, İzmir, Turkiye.
Turkish journal of medical sciences
|December 30, 2024
概括
在土耳其,心力衰竭的治疗显示出未达到最佳指导方针的医疗疗使用,区域差异很大. 诸如心脏移植和机械设备等先进的治疗方法在所有领域都被严重不足利用.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 医疗保健服务研究 医疗服务研究
背景情况:
- 有效的心力衰竭管理依赖于基于证据的药物和先进的疗法,如机械辅助或移植.
- 社会经济差异显著影响到这些关键的心力衰竭治疗的获取.
- 医疗保健获取和质量的区域差异可能会加剧治疗不平等.
研究的目的:
- 分析和比较在土耳其不同地区使用指南推的医疗和先进的心力衰竭治疗方法.
- 在土耳其内识别心力衰竭治疗可及性和应用方面的差异.
主要方法:
- 从2016年1月1日到2022年12月31日,利用了大约8500万公民的医疗记录.
- 评估了一般人群和土耳其不同地理区域内心力衰竭的医疗和心脏替代治疗机会.
主要成果:
- 贝塔抑制剂是最常被处方的药物;然而,较新的药物,如血管激素受体-尼普利辛抑制剂 (0.6%) 和-葡萄糖携带体两种抑制剂 (11%) 的摄入量较低.
- 植入式心脏转换器除器 (ICD) 和心脏再同步治疗 (CRT) 的利用率最低 (分别为0.8%和0.3%).
- 包括心脏移植和左心室辅助器械 (LVAD) 手术在内的先进疗法率非常低.
结论:
- 针对心力衰竭的指导指导医学治疗在土耳其没有得到最佳的实施,并且在地理上存在显著的差异.
- 土耳其的心脏移植,LVAD手术,CRT和ICD植入率与发达国家相比,无论区域如何,都明显低.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
299
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
299
01:22Heart Failure Drugs: β-Blockers
257
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
257
01:26Heart Failure Drugs: Inotropic Agents
395
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
395
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:22Heart Failure Drugs: Diuretics
273
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
273
01:17Increased pulse rate
620
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
620